Daiwa Securities Group Inc. Immuno Gen, Inc. Transaction History

Daiwa Securities Group Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$12.46 - $29.95 $2,566 - $6,169	206 Added 23.2%	1,094 $32,000
Q4 2022 Feb 06, 2023	BUY	$4.55 - $6.31 $887 - $1,230	195 Added 28.14%	888 $4,000
Q3 2021 Nov 05, 2021	BUY	$5.02 - $6.59 $1,551 - $2,036	309 Added 80.47%	693 $4,000
Q4 2020 Feb 04, 2021	SELL	$3.7 - $7.66 $2,264 - $4,687	-612 Reduced 61.45%	384 $2,000
Q3 2020 Nov 02, 2020	BUY	$3.45 - $4.89 $520 - $738	151 Added 17.87%	996 $4,000
Q4 2019 Jan 31, 2020	SELL	$2.25 - $5.8 $247 - $638	-110 Reduced 11.52%	845 $4,000
Q3 2019 Nov 04, 2019	BUY	$2.22 - $3.39 $497 - $759	224 Added 30.64%	955 $2,000
Q1 2018 May 02, 2018	BUY	$6.7 - $12.95 $4,897 - $9,466	731 New	731 $8,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.